Mast Therapeutics Initiates Sub-Study Within Phase 3 EPIC Trial Sub-study will investigate effects of MST-188 on tissue oxygenation in sickle cell disease patients experiencing a vaso-occlusive...
Mast Therapeutics Announces New Data Supporting MST-188 In Sickle Cell Disease MST-188 decreased a marker of inflammation and red blood cell aggregation (50% reduction relative to control) Data...
Mast Therapeutics Signs Definitive Agreement To Acquire Aires Pharmaceuticals, Inc. - All-stock transaction - Conference call to discuss pending acquisition today at 8:30am Eastern Time PR...
Mast Therapeutics To Present At The Rodman & Renshaw 15th Annual Healthcare Conference On September 10 PR Newswire SAN DIEGO, Sept. 3, 2013 SAN DIEGO, Sept. 3, 2013 /PRNewswire/ -- Mast...
ADVENTRX Completes Name Change To "Mast Therapeutics, Inc."; New Ticker Symbol: "MSTX" PR Newswire SAN DIEGO, March 11, 2013 SAN DIEGO, March 11, 2013 /PRNewswire/ -- ADVENTRX...
ADVENTRX Announces Corporate Name Change To "Mast Therapeutics, Inc."; Ticker Symbol Change To "MSTX" Name and ticker symbol changes effective March 11, 2013 PR Newswire SAN...
Adventrx To Develop ANX-188 For Complications Of Arterial Disease - Seeking orphan drug designation in acute limb ischemia (ALI) - Phase 2 clinical proof-of-concept in ALI planned for late...
ADVENTRX Reviews Data Supporting Development Of ANX-188 In New Indications - Platform includes over 100 pharmacology studies, 15 clinical studies and 2,500 patient exposures - ANX-188 phase...
ADVENTRX To Present At The Cowen And Company 33rd Annual Health Care Conference On March 4 PR Newswire SAN DIEGO, Feb. 25, 2013 SAN DIEGO, Feb. 25, 2013 /PRNewswire/ -- ADVENTRX Pharmaceuticals...
ADVENTRX Initiates Thorough QT/QTc Clinical Study Of ANX-188 PR Newswire SAN DIEGO, Feb. 11, 2013 SAN DIEGO, Feb. 11, 2013 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관